Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALT-711 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| ALT-711 | DRUG | - |
Inclusion Criteria * Men or women at least 50 years of age. * Screening diagnosis of isolated systolic hypertension, defined as systolic blood pressure \>150 mm Hg and diastolic blood pressure \<90 mm Hg (office blood pressure measurements) and systolic blood pressure \>140 mm Hg (measured by 24-ho...
ALT-711 is an investigational small molecule being developed for the treatment of hypertension, specifically studied in patients with hypertension and left ventricular hypertrophy. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
ALT-711 is a small molecule being studied for its effects on hypertension and left ventricular hypertrophy. The specific molecular target of ALT-711 has not been disclosed in available clinical trial information, so its mechanism of action is not fully characterized in public data.
ALT-711 is being developed by cbdMD, Inc., a company traded on the NYSE American under the ticker symbol YCBD. The company is conducting clinical research on this investigational drug for cardiovascular indications.
ALT-711 is in Phase 2 clinical development. It has completed one Phase 2 trial, the SILVER Study (NCT00045994), which enrolled 180 participants. The drug remains investigational and has not received FDA approval for any indication.
ALT-711 has one completed clinical trial, the SILVER Study (NCT00045994), titled 'Systolic Hypertension Interaction With Left Ventricular Remodeling.' This Phase 2 study enrolled 180 participants with hypertension and left ventricular hypertrophy, was randomized and double-blind, and has been completed.
ALT-711 is not known to have alternative names in the available clinical trial data. It is identified solely as ALT-711 in the SILVER Study (NCT00045994) and related development records.